What this is
- How it works
- How it works isn't classified yet
- Tested for
- Relapsed or Refractory Multiple Myeloma (2 trials)
- Main trialPhase 3
- “The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.”In the company’s words, NCT07138209 on ClinicalTrials.gov
Other drugs for Relapsed or Refractory Multiple Myeloma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up2
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Recruiting | Nov 2027 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | |
| Phase 1Unknown | 31 Dec 2024 | A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026